Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULFACETAMIDE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULFACETAMIDE SODIUM.
MICROSUL vs SULFACETAMIDE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic